###begin article-title 0
###xml 94 102 <span type="species:ncbi:9606">Patients</span>
N-terminal Pro-Brain Natriuretic Peptide Levels Predict Left Ventricular Systolic Function in Patients with Chronic Kidney Disease
###end article-title 0
###begin p 1
###xml 445 446 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 645 646 645 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
###xml 1237 1245 <span type="species:ncbi:9606">patients</span>
N-terminal pro-brain natriuretic peptide (NT-proBNP) can be a useful marker for left ventricular (LV) dysfunction in patients without kidney disease. This study was conducted to clarify the relationship between NT-proBNP and LV systolic function in patients with decreased renal function. We studied 256 chronic kidney disease (CKD) patients, patients on dialysis were excluded. The median glomerular filtration rate was 24 (13-36) mL/min/1.73 m2 and the median NT-proBNP was 4,849 (1,310-19,009) pg/mL. The prevalence of LV systolic dysfunction increased from the lower to the upper NT-proBNP quartiles (I, 17%; II, 34%; III, 61%; and IV, 72%; p<0.001 for trend). The NT-proBNP quartile was an independent predictor of LV systolic dysfunction after adjustment for renal function, compared with quartile I: II, odds ratio (OR) 3.99 (95% confidence interval [CI],1.34-11.93); III, OR 11.28 (95% CI, 3.74-33.95); and IV, OR 36.97 (95% CI, 11.47-119.1). Area under the curve and optimum cut points for NT-proBNP to detect LV systolic dysfunction were 0.781 and 2,165 pg/mL in CKD stage 3, 0.812 and 4,740 pg/mL in CKD stage 4, and 0.745 and 15,892 pg/mL in CKD stage 5. The NT-proBNP level was a predictor of LV systolic dysfunction in CKD patients. Optimum cut points should be stratified according to renal function.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 128 136 <span type="species:ncbi:9606">Patients</span>
###xml 416 424 <span type="species:ncbi:9606">patients</span>
It is estimated that more than 10% of adults have chronic kidney disease (CKD), and its prevalence is gradually increasing (1). Patients with chronic kidney disease are at increased risk of cardiovascular death (2). Left ventricular (LV) systolic dysfunction is a common terminal pathway for a variety of heart diseases. The presence of LV systolic dysfunction is associated with high morbidity and mortality in CKD patients (3). However, LV systolic dysfunction is difficult to identify based solely on the clinical history and physical examination, because neither is specific nor sensitive (4, 5). Although echocardiography is the current "gold standard" for evaluation of cardiac dysfunction (3), it is expensive and not always readily available.
###end p 3
###begin p 4
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 525 533 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
###xml 844 852 <span type="species:ncbi:9606">patients</span>
Recently, brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) have been extensively studied as useful biochemical markers of ventricular dysfunction and heart failure in the general population (5-8). The kidney appears to play an important role in the clearance of NT-proBNP. Several studies have demonstrated that impaired renal function increases NT-proBNP levels, independent of ventricular function (9, 10). Therefore, diagnostic value of NT-proBNP to predict LV systolic function in patients with significant renal impairment remains unclear. Moreover, potential cut points of NT-proBNP to detect LV systolic dysfunction in patients with CKD has not been systematically evaluated. For these reasons, we undertook this study to evaluate whether NT-proBNP levels could predict ventricular dysfunction in patients with established CKD.
###end p 4
###begin title 5
MATERIALS AND METHODS
###end title 5
###begin title 6
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 6
###begin p 7
###xml 358 359 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 564 572 <span type="species:ncbi:9606">patients</span>
###xml 638 646 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
###xml 816 824 <span type="species:ncbi:9606">patients</span>
###xml 849 857 <span type="species:ncbi:9606">patients</span>
###xml 863 871 <span type="species:ncbi:9606">patients</span>
We enrolled retrospectively adult patients with CKD who visited the outpatient clinic of the Department of Nephrology or the emergency room between March 2003 and March 2005 on whom we performed both NT-proBNP measurement and echocardiography. We excluded patients undergoing dialysis or those with a glomerular filtration rate (GFR) greater 60 mL/min/1.73 m2. A total of 274 patients were identified. We then excluded 18 patients who were finally diagnosed as having pulmonary diseases such as pulmonary thromboembolism or pneumonia. This left a final set of 256 patients to be analyzed. The causes of CKD were diabetic nephropathy (155 patients), hypertensive nephrosclerosis (34 patients), chronic glomerulonephritis (25 patients), autosomal dominant polycystic kidney disease (five patients), other causes (four patients) and unknown causes (33 patients). 78 patients were enrolled in outpatient clinics and others were enrolled in emergency room.
###end p 7
###begin title 8
Clinical variables
###end title 8
###begin p 9
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 560 561 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 596 597 596 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 636 637 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 653 654 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 196 203 <span type="species:ncbi:9606">patient</span>
Patients' demographic and clinical information were obtained by chart review. A diagnosis of diabetes, hypertension, and coronary artery disease (CAD) were included if they were identified in the patient's history and/or by physical examination. CAD was defined as documented myocardial infarction, coronary artery bypass graft surgery, or percutaneous coronary intervention. The GFR was estimated using the abbreviated Modification of Diet in Renal Disease formula (1). Each estimated GFR was categorized into one of three groups as less than 15 mL/min/1.73 m2 (CKD stage 5), 15-29 mL/min/1.73 m2 (CKD stage 4), and 30-59 mL/min/1.73 m2 (CKD stage 3) (1).
###end p 9
###begin title 10
Echocardiographic measurement and definition
###end title 10
###begin p 11
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
Echocardiography was performed as per our standard laboratory protocol by one of five expert sonographers. Findings were analyzed to quantify LV ejection fraction (EF) and LV mass. LV mass was determined by using the formula of Devereux et al. (11) which was adjusted for height. Left ventricular hypertrophy (LVH) was considered to be present when the LV mass index was greater than two standard deviations above the mean of the respective gender control group. The EF was calculated by the Simpson method, using end-diastolic volume and end-systolic volume measurements. LV systolic dysfunction was defined as an LV EF of 50% or less.
###end p 11
###begin title 12
Assay for NT-proBNP
###end title 12
###begin p 13
Blood samples were drawn routinely in lithium heparin tubes and centrifuged at 1,000 g for 12 min. The plasma was used for measurement of NT-proBNP using a commercially available immunoassay (Elecsys proBNP; Roche Diagnostic Corp, Indianapolis, IN, U.S.A.) on an Elecsys 1,010 analyzer according to the manufacturer's directions. The measurable range of the NT-proBNP assay was up to 35,000 pg/mL.
###end p 13
###begin title 14
Statistical analysis
###end title 14
###begin p 15
###xml 448 449 448 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Data for continuous variables were expressed as median and interquartile ranges. Categorical variables were expressed as absolute numbers and percentages. Comparisons between three or more data groups were analyzed by a nonparametric (Kruskal-Wallis) test for continuous variables and by a likelihood ratio test for trends for categorical variables. To assess the independent contribution to LV systolic dysfunction, we used logistic regression. A p value of less than 0.05 was considered to be statistically significant. Separate receiver operating characteristic (ROC) curves were generated for NT-proBNP and detection of LV systolic dysfunction, as a function of GFR categories. All statistical analyses for this study were conducted with SPSS 11.0 for Windows.
###end p 15
###begin title 16
RESULTS
###end title 16
###begin p 17
###xml 379 380 379 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 614 621 614 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 105 108 <span type="species:ncbi:9606">men</span>
###xml 117 122 <span type="species:ncbi:9606">women</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 285 293 <span type="species:ncbi:9606">patients</span>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
###xml 623 631 <span type="species:ncbi:9606">Patients</span>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
The demographics of the study patients were as follows. The median age was 66 (58-74) yr. There were 149 men and 107 women. The most prominent symptoms were shortness of breath in 111 patients, chest discomfort in 45 patients, peripheral edema in 18 patients, and other symptoms in 59 patients. Twenty-three patients were asymptomatic. The median GFR was 24 (13-36) mL/min/1.73 m2 and the median NT-proBNP level was 4,849 (1,310-19,009) pg/mL. LVH was present in 77% of the patients and 118 (46%) had LV systolic dysfunction. Clinical and echocardiographic findings stratified by NT-proBNP quartiles are listed in Table 1. Patients in the upper NT-proBNP quartiles showed higher New York Heart Association function classes. Orthopnea and lower extremity edema were observed more often in patients in upper NT-proBNP quartiles. Diabetes, hypertension, and CAD were also more prevalent in the upper NT-proBNP quartiles. Median estimated GFR and median LV EF decreased from the lower to the upper NT-proBNP quartiles. The prevalence of LV systolic dysfunction increased from 17% in the lowest quartile to 72% in the highest quartile.
###end p 17
###begin p 18
###xml 136 143 136 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
We classified patients by CKD stage, with 87 (34%) patients with CKD stage 3, 93 (36%) with CKD stage 4, and 76 (30%) with CKD stage 5. Table 2 shows clinical and echocardiographic findings according to CKD stages. Orthopnea and lower extremity edema were observed more often in patients with advanced stage of CKD.
###end p 18
###begin p 19
###xml 0 6 0 6 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 178 179 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
Fig. 1 shows median NT-proBNP levels according to LV systolic function and CKD stage. The median NT-proBNP level increased progressively with lower LV EF in each CKD stages (all p<0.001 for trend). Also the median NT-proBNP level increased from CKD stage 3 to stage 5 in each LV EF groups (all p<0.001 for trend). Of note is that CKD stage 5 patients with normal LV systolic function had NT-proBNP levels similar to those in CKD stage 3 patients with LV EF of less than 40% (8,859 [1,672-21,831] pg/mL vs. 8,026 [2,605-17,994] pg/mL).
###end p 19
###begin p 20
###xml 458 466 <span type="species:ncbi:9606">Patients</span>
Multiple logistic regression analyses were performed to determine whether the NT-proBNP level could independently predict the presence of LV systolic dysfunction. The NT-proBNP quartile was found to be an independent predictor of LV systolic dysfunction after adjustment for age, gender, CAD, diabetes, hypertension, GFR, hemoglobin levels, and LVH. The odds ratio of having LV systolic dysfunction increased progressively in the higher NT-proBNP quartiles. Patients in the highest quartile had nearly 37-fold increased odds of having LV systolic dysfunction, compared with those in the lowest quartile (odds ratio 36.97; 95% CI, 11.47 to 119.1). The NT-proBNP quartile was also an independent predictor of having an LV EF less than 40%.
###end p 20
###begin p 21
###xml 124 131 122 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2A</xref>
###xml 560 567 556 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2B</xref>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
ROC curves for NT-proBNP to detect LV systolic dysfunction (LV EF </=50%), and for each of the CKD stages, are presented in Fig. 2A. AUC and optimum cut points were 0.781 and 2,165 pg/mL, 0.812 and 4,740 pg/mL, and 0.745 and 15,892 pg/mL in patients with CKD stage 3, 4, and 5. Using these levels, the sensitivity and specificity of NT-proBNP were 73% and 69%, 76% and 77%, and 74% and 74% in CKD stage 3, 4, and 5, respectively. AUC to detect severe LV systolic dysfunction (LV EF </=40%) were 0.780, 0.793, and 0.802 for CKD stage 3, 4, and 5, respectively (Fig. 2B). Optimum cut points for NT-proBNP increased progressively with CKD stage.
###end p 21
###begin title 22
DISCUSSION
###end title 22
###begin p 23
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
###xml 526 534 <span type="species:ncbi:9606">patients</span>
###xml 951 959 <span type="species:ncbi:9606">patients</span>
This study demonstrates that NT-proBNP was an independent predictor of LV systolic dysfunction in patients with established CKD. Although NT-proBNP level was increased with decreasing GFR, the NT-proBNP level was negatively associated with LV EF independent of renal dysfunction. Optimum cut points of NT-proBNP to detect LV systolic dysfunction were much higher in CKD patients than those reported in the general population and these were increased progressively with lower renal function. These results suggest that even in patients with advanced renal dysfunction, the measurement of NT-proBNP level might be of benefit in predicting LV systolic function in the setting of suspected heart failure and that the NT-proBNP level should be interpreted along with values for renal function in order to predict LV systolic dysfunction. If cut points without adjustment for renal function are applied, the usefulness of NT-proBNP levels is limited in CKD patients.
###end p 23
###begin p 24
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
###xml 526 534 <span type="species:ncbi:9606">patients</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
###xml 643 651 <span type="species:ncbi:9606">patients</span>
The diagnostic and prognostic roles of NT-proBNP have been well established in a variety of cardiac diseases (9, 10, 12-15). Most investigators have excluded CKD patients from their studies because of potentially elevated levels of the peptide (9, 10, 12-15). However, an easily measurable biomarker for cardiac disease is sorely needed in CKD patients, because symptoms mimicking congestive heart failure occur very often among them (3). Our study suggests that NT-proBNP measurement might be used as a screening tool in CKD patients with clinically suspected LV systolic dysfunction. Compared with patients in the lowest NT-proBNP quartile, patients in the upper quartiles had an increased probability of LV systolic dysfunction, based on multivariate analysis.
###end p 24
###begin p 25
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1208 1210 1208 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1212 1214 1212 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 506 514 <span type="species:ncbi:9606">patients</span>
###xml 780 788 <span type="species:ncbi:9606">patients</span>
###xml 1154 1162 <span type="species:ncbi:9606">patients</span>
Previous studies investigating the clinical implications of NT-proBNP measurement in CKD patients showed that NT-proBNP quartile were associated with LVH and coronary artery disease in stable pre-ESRD patients (16-19). In our current study, the prevalence of LVH increased in the higher NT-proBNP quartiles. However, after adjustment for the GFR, levels of NT-proBNP alone could not predict the presence of LVH (data not shown). A thickened LV wall might lead to an increased secretion of NT-proBNP in CKD patients, just as in subjects without kidney disease (11). We presume that the effect of LVH on the NT-proBNP level was much smaller than the effect of impaired renal function or LV systolic dysfunction. Accordingly, NT-proBNP was not an independent predictor of LVH in our patients with a high prevalence of LV systolic dysfunction and advanced renal dysfunction. Previous studies showed lower prevalence of LV systolic function than our study and the relation between LV systolic function and NT-proBNP levels were not evaluated systemically. Although a few studies have shown that NT-proBNP level was associated with LV systolic function in CKD patients, independent association were not evaluated (20, 21).
###end p 25
###begin p 26
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 302 304 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 563 565 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
It is well established that impaired renal function is associated with an elevated NT-proBNP level (9, 10, 14, 18). The NT-proBNP level is likely to increase corresponding to the severity of renal dysfunction by several possible mechanisms. Decreased renal clearance may play a role, at least in part (22). Concomitant anemia and cardiac overload may contribute to an increase in the NT-proBNP level in CKD patients, in the same manner as for the BNP level (22). Elevated NT-proBNP may also reflect silent myocardial infarction, LVH or diastolic dysfunction (18, 23).
###end p 26
###begin p 27
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
###xml 138 146 <span type="species:ncbi:9606">patients</span>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
The high prevalence of LV dysfunction seen in our study is noteworthy. There were 46% of patients with LV systolic dysfunction and 77% of patients with LVH. Higher prevalence of LV systolic dysfunction than in previous studies on CKD patients (16-18) could be explained that we included patients who need emergent treatment and most patients were symptomatic.
###end p 27
###begin p 28
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 409 417 <span type="species:ncbi:9606">patients</span>
###xml 705 713 <span type="species:ncbi:9606">patients</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
Several limitations apply to this study. First, we did not consider volume status or silent myocardial ischemia. Both might be associated with NT-proBNP levels in CKD patients. However, it is difficult to evaluate the exact volume status or assess silent myocardial ischemia based solely on clinical findings. Second, the NT-proBNP assay used in the study has an upper limit of 35,000 pg/mL. 14% of our study patients had a NT-proBNP level equal or greater to this. Therefore, we could not analyze direct correlations of the NT-proBNP level with GFR or LVEF. Instead, we stratified by quartiles to analyze the relationship between NT-proBNP levels and LV systolic function. Third, the fact that our study patients were relatively old limits the generalizability of our finding in the whole CKD patients. Fourth, GFRs estimated using the abbreviated MDRD study equation were used to classify CKD stages. Although, the MDRD study equation has been used widely in large epidemiologic studies and in clinical practice, it has not been validated for the Korean population.
###end p 28
###begin p 29
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
In summary, although the NT-proBNP level is increased in the majority of patients with renal dysfunction, higher NT-proBNP levels were associated with a higher prevalence of LV systolic dysfunction, independent of renal function. The measurement of NT-proBNP levels might be of benefit in the prediction of LV systolic function in CKD patients with suspected congestive heart failure. However, renal function must be taken into consideration when NT-proBNP measurement is used as a diagnostic tool. A prospective study is needed to determine the diagnostic value and optimal cutoff levels for NT-proBNP for predicting LV dysfunction in CKD patients.
###end p 29
###begin p 30
###xml 40 79 40 79 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IN-SUNG Foundation for Medical Research</funding-source>
###xml 84 106 84 106 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Samsung Medical Center</funding-source>
This work was supported by a grant from IN-SUNG Foundation for Medical Research and Samsung Medical Center.
###end p 30
###begin article-title 31
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification
###end article-title 31
###begin article-title 32
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial
###end article-title 32
###begin article-title 33
###xml 75 83 <span type="species:ncbi:9606">patients</span>
K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients
###end article-title 33
###begin article-title 34
The limited reliability of physical signs for estimating hemodynamics in chronic heart failure
###end article-title 34
###begin article-title 35
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
###end article-title 35
###begin article-title 36
Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population
###end article-title 36
###begin article-title 37
Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations
###end article-title 37
###begin article-title 38
Plasma brain natriuretic peptide in assessment of acute dyspnoea
###end article-title 38
###begin article-title 39
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease
###end article-title 39
###begin article-title 40
N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function
###end article-title 40
###begin article-title 41
###xml 149 157 <span type="species:ncbi:9606">patients</span>
Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy
###end article-title 41
###begin article-title 42
Prognostic impact of plasma N-terminal probrain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial
###end article-title 42
###begin article-title 43
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction
###end article-title 43
###begin article-title 44
###xml 145 153 <span type="species:ncbi:9606">patients</span>
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy
###end article-title 44
###begin article-title 45
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy
###end article-title 45
###begin article-title 46
###xml 62 70 <span type="species:ncbi:9606">patients</span>
B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy
###end article-title 46
###begin article-title 47
###xml 183 191 <span type="species:ncbi:9606">patients</span>
N-terminal pro-b-type natriuretic peptide and b-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients
###end article-title 47
###begin article-title 48
N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis
###end article-title 48
###begin article-title 49
Amino-terminal pro-B-type natriuretic peptide testing in renal disease
###end article-title 49
###begin article-title 50
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Brain natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP) and cardiac troponin T (cTnT) as markers of cardiac diseases in stable hemodialysis patients
###end article-title 50
###begin article-title 51
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and left ventricular function in patients with chronic renal failure
###end article-title 51
###begin article-title 52
Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF
###end article-title 52
###begin article-title 53
Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings
###end article-title 53
###begin p 54
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Median NT-proBNP level according to left ventricular systolic function and CKD stage (p<0.01 for both inter-CKD stages and inter-LV EF groups).
###end p 54
###begin p 55
Receiver operating characteristic curves for NT-proBNP to detect LV EF </=50% (A) and LV EF </=40% (B) in each stages of CKD.
###end p 55
###begin p 56
Clinical characteristics and echocardiographic findings according to NT-proBNP quartiles
###end p 56
###begin p 57
Values expressed as median (interquartile range). Categorical data expressed as number (percent).
###end p 57
###begin p 58
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
*We could not assess information regarding these variables in some patients (less than 10% of the study patients). Thus, the sums of numbers given do not equal 256.
###end p 58
###begin p 59
NYHA, New York Heart Association; LE, lower extremity; GFR, glomerular filtration rate; LV MI, left ventricular mass index; LV EF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-brain natriuretic peptide.
###end p 59
###begin p 60
Clinical characteristics and echocardiographic findings according to CKD stages
###end p 60
###begin p 61
Data expressed as number (percent).
###end p 61
###begin p 62
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
*We could not assess information regarding these variables in some patients. Thus, the sums of numbers given do not equal 256.
###end p 62
###begin p 63
NYHA, New York Heart Association; LE, lower extremity; LVH, left ventricular hypertrophy; LV EF, left ventricular ejection fraction.
###end p 63
###begin p 64
Multiple logistic regression models-association between NT-proBNP quartiles and LV systolic function
###end p 64
###begin p 65
These models also included age, gender, coronary artery disease, diabetes, hypertension, glomerular filtration rate, hemoglobin, and left ventricular hypertrophy.
###end p 65
###begin p 66
LV EF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide.
###end p 66

